- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05407220
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
June 2, 2022 updated by: Hanmi Pharmaceutical Company Limited
A Randomized, Open-Label, Single-Dose Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
A Randomized, Open-Label, Single-Dose Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Yangji Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Age 19~45 years in healthy male volunteers
- Weight ≥ 55kg and BMI 18 ~ 30 kg/m^2
- Subjects who agree to use medically accepted dual contraceptives up to 14 days after the last administration date of the clinical trial drug and not to provide sperm.
- Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing
Exclusion Criteria:
- Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
- Subjects who judged ineligible by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: group1
Period1: HCP1904-1
|
take it once per period
|
Experimental: group2
Period1: HCP1904-3
|
take it once per period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of Losartan
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
AUC last of Losartan
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
AUC inf of Losartan
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Tmax of Losartan
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
t1/2 of Losartan
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
CL/F of Losartan
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Vd/F of Losartan
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Cmax of EXP3174
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
AUC last of EXP3174
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
AUC inf of EXP3174
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Tmax of EXP3174
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
t1/2 of EXP3174
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
CL/F of EXP3174
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Vd/F of EXP3174
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Cmax of Chlorthalidone
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
AUC last of Chlorthalidone
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
AUC inf of Chlorthalidone
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Tmax of Chlorthalidone
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
t1/2 of Chlorthalidone
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
CL/F of Chlorthalidone
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Vd/F of Chlorthalidone
Time Frame: Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
pharmacokinetic evaluation
|
Day 1, 2, 3, 4, 5, 7 : pre-dose(0 hour)~144hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 8, 2022
Primary Completion (Anticipated)
July 16, 2022
Study Completion (Anticipated)
July 16, 2022
Study Registration Dates
First Submitted
May 27, 2022
First Submitted That Met QC Criteria
June 2, 2022
First Posted (Actual)
June 7, 2022
Study Record Updates
Last Update Posted (Actual)
June 7, 2022
Last Update Submitted That Met QC Criteria
June 2, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- HM-CHORUS-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on HCP1904-1
-
Hanmi Pharmaceutical Company LimitedCompleted
-
Hanmi Pharmaceutical Company LimitedCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedHypertensionKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedHypertensionKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedHypertensionKorea, Republic of
-
Orasis Pharmaceuticals Ltd.Completed
-
University of ThessalyCompleted
-
University of Sao Paulo General HospitalCompleted
-
Chulalongkorn UniversityCompletedAllergic RhinitisThailand
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil